Skip to content
OpenCapital
Get started

Edwards Lifesciences EW Q1 2026 earnings

Reported April 23, 2026 · After market close

Revenue$1.6BBeat by $51.8MDiluted EPS$0.78Beat by $0.05
Revenue estimate$1.6B
EPS estimate$0.73

Next report

Jul 23, 2026 (In 1 week)
Revenue estimate$1.7B
EPS estimate$0.73

Financials

Q1 2026

Income statement

See full
Revenue$1.6B+16.7%
Gross profit$1.3B+15.7%
Operating income$477.6M+21.0%
Net income$380.7M+6.3%
EPS (diluted)$0.66+8.2%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation & ratios

Valuation

as of 07/09/26
See full
Market cap$53.92B+8.7%
Enterprise value$52.17B+11.0%
P/E49.2×+37.3×
P/S8.6×-0.4×

Profitability

See full
Gross margin77.9%-1.6pp
Operating margin21.4%-4.4pp
Net margin17.4%-58.3pp
FCF margin17.3%—

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Segments

By segment

See full
United States$937.6M+11.8%
Europe$442.6M+29.5%
Rest of World$177.8M+18.4%
Japan$90.6M+10.8%

By product

See full
Transcatheter Aortic Valve Replacement$1.2B+14.4%
Surgical$276.2M—
Transcatheter Mitral and Tricuspid Therapies$175.1M+52.0%

Versus estimates

Revenue

Q1 2026$1.6BBeat by $51.8M
Q4 2025$1.6BBeat by $22.7MQ3 2025$1.6BBeat by $55.3MQ2 2025$1.5BBeat by $44.2MQ1 2025$1.4BBeat by $12.2MQ4 2024$1.4BBeat by $26.9M

Diluted EPS

Q1 2026$0.78Beat by $0.05
Q4 2025$0.58Miss by $0.04Q3 2025$0.67Beat by $0.07Q2 2025$0.67Beat by $0.05Q1 2025$0.64Beat by $0.04Q4 2024$0.59Beat by $0.04

Ask the moment Edwards Lifesciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Edwards Lifesciences report Q1 2026 earnings?
Edwards Lifesciences (EW) reported Q1 2026 earnings on April 23, 2026 after market close.
What were Edwards Lifesciences's Q1 2026 revenue and EPS?
Edwards Lifesciences reported revenue of $1.6B and diluted EPS of $0.78 for Q1 2026.
Did Edwards Lifesciences beat estimates in Q1 2026?
Revenue beat the consensus estimate of $1.6B by $51.8M. EPS beat the consensus estimate of $0.73 by $0.05.
How did Edwards Lifesciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.7% from $1.4B a year earlier and diluted EPS grew 21.9% from $0.64.
Where can I find Edwards Lifesciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001099800-26-000021) and the 10-Q periodic report (0001099800-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.